Download the abstract book

CTGCT Day 2026

ADVANCES IN CELL, TISSUE, AND GENE THERAPIES

11 November 2026

Ljubljana, Slovenia

Venue

Grand Hotel Union Eurostars

Miklošičeva cesta 1, Ljubljana, Slovenia

PARTNERS

UCL · UMC Utrecht · Technische Universität Dresden · Charité Universitätsmedizin Berlin

GOLD SPONSORS

eatris connect · omega · Miltenyi Biotec · LABORMED · SARTORIUS

SILVER SPONSORS

KEMOMED Bringing Solutions · mediline · Optimatika · LKB Excellence in Routine and Science

BRONZE SPONSOR

KEFO

CTGCT Centre for the Technologies of Gene and Cell Therapy

National Institute of Chemistry

FUNDERS

I FEEL SLOVENIA

Co-funded by the European Union

UKRI UK Research and Innovation

Conference Programme

Start	End	Speaker	Title
08:00	08:30	Registration	
08:30	08:40	Welcome and Opening Remarks	
		Session 1	**ATMP Production and Translation**
08:40	09:15	Zsolt Sebestyen, UMC Utrecht	Biomimetic strategies to guide rational immune receptor-based drug development
09:15	09:35	Luka Fajs, Bio-ReCell d.o.o.	Closed-System Non-Magnetic Cell Separation and Activation Approaches for T Cell Manufacturing
09:35	09:55	Lenka Součková, Masaryk University	From Clinical Trial to Patient Access: Practical Lessons from the First Czech Hospital Exemption for an Academic ATMP
09:55	10:15	Matija Povh, Sartorious BIA Separations d.o.o.	Improved Development of LNP Formulation for Organ Targeting using Chromatographic Tools
10:15	10:45	Coffee Break and Poster Session	**Sponsor Presentation: Omega ThermoFisher**
		Session 2	**From In Vivo Models to Treatments**
10:45	11:20	Jan Procházka, Czech Centre for Phenogenomics	Integrated Phenotyping: From Disease Mechanisms to Therapeutic Endpoints
11:20	11:40	Tomaž Martini, University of Maribor	Novel-Modality Therapeutic Opportunities in Hyperlipidemia Based on the Discovery of the Sexually Dimorphic Hepatic Cycle of Very-Low-Density Lipoproteins
11:40	12:00	Giulia Bortolussi, International Centre for Genetic Engineering and Biotechnology	HepCycle-Track Quantifies Hepatocyte Proliferation to Define Therapeutic Timing as a Precision Parameter for Gene Therapy and Genome Editing
12:00	12:20	Špela Malenšek, National Institute of Chemistry	Immunoengineering genetically encoded chimeric PCSK9 vaccine against hypercholesterolemia.
12:20	14:00	Break	**Sponsor Presentation: Sartorius**
		Session 3	**Advances in Gene, Cell and Tissue Therapies**
14:00	14:35	Massimo Dominici, University of Modena and Reggio Emilia	Engineering Cells to Defeat Refractory Solid Tumors: From MSC-Based Therapeutics to CAR-Driven Immunotherapy
14:35	14:55	Aleksandar Janev, University of Ljubljana	Human Amniotic Membrane Preparations Exert a Tumour-Selective Anti-Cancer Effect in Bladder Cancer Across 2D, 3D, and Patient-Derived Models
14:55	15:15	Petra Sušjan Leite, National Institute of Chemistry	Making One Copy Count — RNA-Based Therapeutic Strategies in CTNNB1 Haploinsufficiency
15:15	15:35	Duško Lainšček, National Institute of Chemistry	Decoupling reactogenicity from efficacy enables safer mRNA vaccines, AAV gene delivery, and in vivo base editing
15:35	16:05	Coffee Break and Poster Session	**Sponsor Presentation: Miltenyi Biotec, Labormed**
		Session 4	**Cellular Models for Mechanistic and Safety Studies**
16:05	16:40	Sebastian Diecke, Max Delbruck Center for Molecular Medicine	Pluripotent Stem Cells, Automation, Disease Modeling and beyond
16:40	17:00	Nina Krako Jakovljević, University Clinical Centre of Serbia	Altered Mitochondrial Respiratory Function and Morphology of Palmitate Induced Hepatocellular Carcinoma Cells: Model of Hepatic Insulin Resistance and Lipotoxcity
17:00	17:20	Bernarda Majc, National Institute of Biology	Overcoming glioblastoma resistance: enhancing standard and nk cell therapies through tgf-v pathway inhibition
17:20	17:40	David Morrow, EATRIS	From Innovation to Access: How Effective European Collaboration Can Transform the ATMP Landscape
17:40	17:50	**Closing Remarks**	